July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Efficacy and safety of aflibercept in diabetic macular edema: real life study
Author Affiliations & Notes
  • Linda Hrarat
    Bobigny, Hopital Avicenne, NOGENT SUR MARNE, France
  • Audrey Giocanti Auregan
    Bobigny, Hopital Avicenne, NOGENT SUR MARNE, France
  • Sylvia Buffet
    Bobigny, Hopital Avicenne, NOGENT SUR MARNE, France
  • Franck Fajnkuchen
    Bobigny, Hopital Avicenne, NOGENT SUR MARNE, France
  • Footnotes
    Commercial Relationships   Linda Hrarat, None; Audrey Giocanti Auregan, None; Sylvia Buffet, None; Franck Fajnkuchen, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4822. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Linda Hrarat, Audrey Giocanti Auregan, Sylvia Buffet, Franck Fajnkuchen; Efficacy and safety of aflibercept in diabetic macular edema: real life study
      . Invest. Ophthalmol. Vis. Sci. 2018;59(9):4822.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diabetic macular edema (DME) is the leading cause of blindness in diabetic patients. Pivotal studies have demonstrated the efficacy of aflibercept intravitreal injections (IVI) on DME. Our main purpose was to assess the efficacy and safety of aflibercept in treatment naive patients with diabetic macular edema in a real life setting.

Methods : We conducted a retrospective, bi-center study including all consecutive naïve patients diagnosed for DME and treated with aflibercept. The mandatory regimen of treatment was 5 monthly injections followed by bimonthly IVI. Our primary endpoint was the mean change in best-corrected visual acuity (BCVA) between baseline and month 12 of follow-up.

Results : We included 25 eyes of 21 patients. BCVA improved from baseline 61+/-11.7 (30-84) letters until 70.3+/-8.4 (47-85) letters at M6 and 72.6+/-10.3(47-85) letters at M12 after a mean of 6.84 IVI over the 12 first months representing a mean variation of +11.56 letters at M12. 32% gained more than 15 letters and 40% more than 10 letters at M12. 76% of eyes reached the threshold of 70 letters at M12. At baseline the mean CRT was 392+/-61 (304-578) µm and decreased to 288+/-61 (165-466) µm at M6 and 285+/-56 (165-407) at M12 with a mean variation of - 104µm at M6 and - 107µm at M12. 60% of eyes at M12 have completely resolved their edema and reached a flat retina.

Conclusions : We confirmed the significant improvement of functional and anatomical outcomes over a treatment by aflibercept in DME among treatment naïve patients in a real-life setting over a follow-up of 12 months.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×